New NIH Research Results On Treatment Of ‘Central Nervous System Diseases’

Antidepressant May Enhance Drug Delivery To The Brain

NIH Clinical Research Center aerial

New research from the National Institutes of Health found that pairing the antidepressant amitriptyline with drugs designed to treat central nervous system diseases, enhances drug delivery to the brain by inhibiting the blood-brain barrier in rats. The blood-brain barrier serves as a natural, protective boundary, preventing most drugs from entering the brain. The research, performed in rats, appeared online April 27 in the Journal of Cerebral Blood Flow and Metabolism.

Although researchers caution that more studies are needed to determine whether people will benefit from the discovery, the new finding has the potential to revolutionize treatment for a whole host of brain-centered conditions, including epilepsy, stroke,human amyotrophic lateral sclerosis (ALS), depression, and others. The results are so promising that a provisional patent application has been filed for methods of co-administration of amitriptyline with central nervous system drugs.

According to Ronald Cannon, Ph.D., staff scientist at NIH’s National Institute of Environmental Health Sciences (NIEHS), the biggest obstacle to efficiently delivering drugs to the brain is a protein pump called P-glycoprotein. Located along the inner lining of brain blood vessels, P-glycoprotein directs toxins and pharmaceuticals back into the body’s circulation before they pass into the brain.

Illustration of blood-brain barrier.

To get an idea of how P-glycoprotein works, Cannon said to think of the protein as a hotel doorman, standing in front of a revolving door at a lobby entrance. A person who is not authorized to enter would get turned away, being ushered back around the revolving door and out into the street.

“For example, as good as vegetables are for us to eat, they have molecules that could be toxic if they slipped into the brain,” Cannon said. “They don’t get in, because of P-glycoprotein, but this same protector also keeps out helpful therapeutics.”

Cannon and his NIEHS colleagues initially found that amitriptyline significantly reduced P-glycoprotein’s pump activity in brain capillaries from wild-type rats. Later, they saw amitriptyline had the same effect in brain capillaries from genetically modified rats designed to mimic human ALS. In both rat models, amitriptyline turned off P-glycoprotein within 10–15 minutes. When amitriptyline was removed, P-glycoprotein pump activity returned to full-strength.

NIEHS postbaccalaureate fellow David Banks is lead author on the paper and described amitriptyline’s action on P-glycoprotein as rapid and reversible. It’s these advantages that make the therapy so appealing.

“Most inventions developed at the bench don’t make it to the clinic, but I’m hopeful that our findings will translate into better treatment options for doctors and their patients,” Banks said.

Cannon anticipates that administering amitriptyline along with a lower dose of an opioid could relieve pain and reduce the negative side effects, such as constipation and addiction, usually seen with higher doses of prescribed opioids.

“As our nation faces increases in Alzheimer’s disease, autism, and opioid abuse, we’re hopeful that this discovery will help address these serious health challenges,” said NIEHS Director Linda Birnbaum, Ph.D.

NIEHS supports research to understand the effects of the environment on human health and is part of NIH. For more information on environmental health topics, visit www.niehs.nih.gov. Subscribe to one or more of the NIEHS news lists (www.niehs.nih.gov/news/releases/newslist/index.cfm) to stay current on NIEHS news, press releases, grant opportunities, training, events, and publications.

Reference

Banks DB, Chan GNY, Evans RA, Miller DS, Cannon RE. 2017. Lysophosphatidic acid and amitriptyline signal through LPA1R to reduce p-glycoprotein transport at the blood-brain-barrier.

About the National Institutes of Health (NIH):

NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

[Source: National Institutes of Health -/- Media Relations]
[Photo credits-Featured Image: inserted by openeyesopinion.com credits embedded]

###


 




 



Click here for reuse options!
Copyright 2017 openeyesopinion.com
Share This Post
Share on Facebook0Share on Google+1Tweet about this on TwitterShare on Reddit0Pin on Pinterest0Share on StumbleUpon0Share on LinkedIn0Digg thisShare on Yummly0Share on Tumblr0Buffer this pagePrint this pageEmail this to someone





Related News

  • Baby Boomers – You Need To Keep In Mind That Planning For Retirement Is Not Just About Money
  • Does Climate Change Impact Your Personal Life?
  • The Fundamental Transformation of America? – Over 100 Colleges And Universities In The U.S. Offer Academic Programs In ‘Social Justice’
  • U.S. Marines and Navy Hospital Corpsmen Celebrate The 119-Year Relationship Between Corpsmen And Marines
  • U.S. Marines Extend Presence In Norway For Another Year
  • 21 People Dead, 20 Injured In Brazil Bus Crash
  • France – Paris Enduring The ‘Heat Wave’ Rolls Out Anti-Pollution Measures, Free Rental Bikes
  • New York U.S. Army National Guardsman Trains Next Generation Of Shooters
  • Is The ‘Liberal Slanted’ New York Times Experimenting With Balanced Editorial Reporting By Hiring A Conservative Columnist?
  • U.S. Customs Officers Capture 15 Fugitives And Seize $1.4 Million In Drugs
  • U.S. Attorney General Creates ‘National Public Safety Partnership’ To Combat Violent Crime
  • Democrats Have A Problem That Transcends Color Lines: Working-Class Americans
  • What Exactly Is Outrage? – Why There Are Costs To Moral Outrage?
  • U.S. Coast Guard, ‘National Security Cutter’, On Counter Drug Mission Seizes $266 Million Of Cocaine
  • A Retired U.S. Navy Captain Sentenced To Prison For Defense Contracts, Bribery And Fraud Scheme
  • U.S. Navy Vice Admiral Joseph P. Aucoin’s Press Conference On The USS Fitzgerald Collision